key: cord-1003441-yctpudkx authors: Ross, S.; Bortolussi-Courval, E.; Hanula, R.; Lee, T. C.; Wilson, M. G.; Gibson McDonald, E. title: COVID-SAFER: Deprescribing Guidance for Nirmatrelvir-ritonavir Drug Interactions in Older Adults date: 2022-03-04 journal: nan DOI: 10.1101/2022.03.01.22271254 sha: f63ee6239752ed222f4222303bbb576887309525 doc_id: 1003441 cord_uid: yctpudkx Importance: Older adults, at high-risk of developing complications from COVID-19, could benefit from nirmatrelvir-ritonavir, an oral antiviral treatment for outpatients at high risk of complications from COVID-19; however, due to its potent CYP3A4 inhibition, nirmatrelvir-ritonavir is associated with many drug-drug interactions (DDI). Objectives: Identify how common DDIs are between nirmatrelvir-ritonavir, common medications, and PIMs in older adults with polypharmacy. Craft anticipatory deprescribing guidance for PIMs that interact with nirmatrelvir-ritonavir to help prioritize deprescribing resources, and increase the proportion of older adults potentially benefitting from treatment. Design: In this secondary analysis, we retrospectively analyzed all patients in the MedSafer cluster randomized deprescribing trial (N=5698 participants) to investigate the proportion of older adults (age > 65) with polypharmacy ([≥] 5 usual home medications) who would be ineligible for treatment with nirmatrelvir-ritonavir due to pre-existing DDIs. Setting: The setting of the primary study was in medical inpatient units at 11 Canadian acute care hospitals. Participants: Hospitalized persons, age 65 years and older, on 5 or more daily home medications, with an expected survival of 3 months or longer were included in this secondary analysis. Main outcomes and measures: We identified the prevalence of (PIMs), as defined by the MedSafer software. We then developed deprescribing guidance, so clinicians could proactively deprescribe in an effort to increase the proportion of older adults eligible for safe treatment with nirmatrelvir-ritonavir in the event of a SARS-CoV-2 infection. Results: Of 5698 participants, a total of 3869 (68%) were taking a medication with a known nirmatrelvir-ritonavir DDI, and of these 823 (21%) had at least one PIM. Of 823 PIMs, 627 (76%) were medications with a known high risk DDI and 213 (26%) were considered moderate risk DDIs with nirmatrelvir-ritonavir. Many of the PIMs required "advanced deprescribing" and could not simply be stopped, held, or adjusted at the time of nirmatrelvir-ritonavir receipt. Conclusions and relevance: Older adults are at high risk of developing severe complications from COVID-19. Deprescribing PIMs in advance of a COVID-19 infection could increase the proportion of older adults who can safely receive nirmatrelvir-ritonavir, in addition to the usual benefits observed with medication management. Since the beginning of the pandemic, hundreds of thousands of older Americans have died from complications of COVID-19. [1 2] Despite the availability of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination, older adults remain one of the most vulnerable populations in terms of hospitalization and death due to COVID-19. [3] Most recently, there has been a resurgence in cases brought on by new variants such as Omicron. [4] Exponential spread, viral mutations, and waning of immunity support the need for both an agile vaccination strategy and an ongoing urgency to develop and test effective therapies. [4 5] On December 22nd, 2021, the FDA granted an emergency use authorization (EUA) for nirmatrelvir-ritonavir (marketed as Paxlovid), the first oral antiviral for the treatment of COVID-19 [6 7] . Nirmatrelvirritonavir contains co-packaged tablets of nirmatrelvir (2x150 mg) and ritonavir (100 mg) and is indicated for the outpatient treatment of mild-to-moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death. [8] An initial randomized clinical trial of nirmatrelvir-ritonavir demonstrated a reduction in risk of all-cause hospitalization or death by 88% (95% CI [75% -94%]) compared to placebo in high risk, symptomatic, unvaccinated adults with COVID-19. [6 7] Comparatively, it is one of the most effective treatments for COVID-19 outpatients, among a number of novel or repurposed medications already studied. [9 10] During the first wave of the pandemic, one such repurposed medication (hydroxychloroquine) generated significant interest, but ultimately proved to be ineffective in randomized controlled trials. [11] However, hydroxychloroquine shed light on an important issue: All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 4, 2022. ; https://doi.org/10.1101/2022.03.01.22271254 doi: medRxiv preprint many older adults could not safely receive this medication or enroll in clinical trials because of important pre-existing drug-drug interactions (DDIs). [12] Our team conducted an analysis where we theoretically exposed a cohort of 1001 hospitalized older adults to hydroxychloroquine, and found that ~60% of patients had potential DDIs and 43.2% of these involved so-called potentially inappropriate medications (PIMs). [12] With such a large proportion of patients identified with DDIs due to PIMs and polypharmacy, we called for the rationalization of medication lists in older adults with a focus on medication optimization and proactive deprescribing. Millions of treatment courses of nirmatrelvir-ritonavir have now been purchased worldwide. Nirmatrelvir-ritonavir also has a long list of DDIs, limiting its safe use, especially among older adults with polypharmacy. [10] Even with short term use, the ritonavir component strongly inhibits CYP3A4, an important enzyme for the metabolism of many drugs. It therefore has the potential to alter serum concentrations and therefore lead to toxicity or reduced efficacy of several common medications. [10 13] Our aims for the present study were two-fold. The first was to identify how common DDIs are between nirmatrelvir-ritonavir, common medications, and PIMs in older adults with polypharmacy. We hypothesized that many patients would not be able to safely receive this oral antiviral. The second aim was to craft anticipatory deprescribing guidance for PIMs that interact with nirmatrelvir-ritonavir to help prioritize deprescribing resources, and ultimately, to increase the proportion of older adults who could benefit from treatment. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The first COVID-SAFER study was conducted with hydroxychloroquine, using data from the pilot MedSafer study. [12] For this COVID-SAFER: Nirmatrelvir-ritonavir study, we analyzed data from the 5698 patient cluster randomized MedSafer trial, which ran from August 2017 to January 2020. [14] Briefly, inclusion criteria identified patients 65-years and older, taking five or more medications, admitted to one of the 11 study hospitals. Data pertaining to medications and comorbidities were analyzed with the MedSafer deprescribing software. The software applies a ruleset for the identification of PIMs which includes common recommendations from expert groups. [15] [16] [17] MedSafer generates a prioritized, individualized deprescribing report according to the perceived level of medication harm (high, intermediate, or low risk/little added value), and provides the rationale for deprescribing with appropriate tapering protocols where required. [18] The MedSafer trial compared the provision of individualized deprescribing opportunity reports to usual care for the primary outcome of prevention of post-discharge adverse drug events (ADEs) and, among several secondary outcomes, the augmentation of deprescribing of PIMs at hospital discharge. For the present study, we utilized the data from the MedSafer trial as a representative cohort of older adults with polypharmacy. Over 85% of the patients in the MedSafer study were community-dwelling and all the participants had risk factors for developing severe complications from COVID-19, by virtue of age and comorbidity. First, we searched the literature for medications with known DDIs with nirmatrelvirritonavir by examining the product monograph, [8] referring to DDI websites and other publications, [19] and reviewing the exclusion criteria for the randomized controlled trial which led to the EUA (EPIC-HR; NCT04960202). [20] Medications with known interactions were All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 4, 2022. ; https://doi.org/10.1101/2022.03.01.22271254 doi: medRxiv preprint grouped according to the American Hospital Formulary Service (AHFS) classification [21] (Table 1 ) and divided into two categories: chronic medications and medications typically prescribed for a short course (e.g., antibiotics). We theoretically "exposed" the MedSafer trial cohort to treatment with nirmatrelvir-ritonavir (twice daily for 5 days), identified DDIs, and linked these with the associated potentially harmful outcome, such as medication toxicity, cardiac arrhythmias, increased risk of bleeding, respiratory depression, or death. We classified the DDIs as either severe (e.g., cardiac arrhythmias and respiratory depression) moderate (e.g., increased therapeutic drug level/risk of toxicity) or other (e.g., reduced effectiveness of the drug and/or reduced effectiveness of nirmatrelvir-ritonavir). We further identified the risk of an ADE requiring closer monitoring during therapy (e.g., anti-coagulation parameters or behavioral symptoms; Supplemental Table 1 ). Next, we applied the MedSafer rules to determine the proportion of patients receiving one or more PIMs interacting with nirmatrelvir-ritonavir. When present, we also identified the triggering condition associated with each PIM (e.g., orthostatic hypotension, dementia, delirium, renal failure). Finally, we crafted anticipatory deprescribing guidance to avoid potential DDIs. Recommendations were based on the literature and the expert opinion of the authors. [15-17 19] Ideally, we considered a scenario wherein PIMs were proactively deprescribed weeks to months in advance of ever requiring treatment with nirmatrelvir-ritonavir. As we are aware that such an approach is not always feasible, we also crafted mitigation strategies that included: do not coadminister, hold medication, adjust dose, and/or monitor clinically, based on a prior publication by the authors (Supplemental Table 1 ). [12 19] Of note, we did not account for DDIs with over the counter or naturopathic medications. The most important one being St. John's Wort, which cannot be co-administered with All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 4, 2022. ; https://doi.org/10.1101/2022.03.01.22271254 doi: medRxiv preprint nirmatrelvir-ritonavir, as it may lead to loss of virologic response and the possible development of viral resistance. [22 23] Furthermore, as MedSafer did not capture most systemic chemotherapies, these were not included, but are potentially relevant. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The MedSafer [18] trial enrolled 5698 patients 65 years and older who were taking 5 or more medications and survived to hospital discharge. The median age of the cohort was 78 years (IQR 71-86) and 50.2% or participants were female. The most prevalent comorbidities were hypertension (74%), type 2 diabetes (39%), ischemic heart disease (34%), and atrial fibrillation (32%). The median number of daily at-home medications was 10 (IQR [8] [9] [10] [11] [12] [13] [14] , with a median of 2 PIMs (IQR 1-4) identified per participant. Of the 5698 patients, 3869 (68%) were prescribed one or more usual home medications that could interact with nirmatrelvir-ritonavir. The most commonly prescribed medications with known DDIs were oral antithrombotic medications (e.g., apixaban, warfarin, clopidogrel; 2131/5698 or 37%), statins (e.g., atorvastatin; 1901/5698 or 33%), and alpha1-adrenoceptor antagonists (e.g., alfuzosin, tamsulosin; 779/5698 or 14%) ( Table 2) Table S2 ). All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. In a representative trial population of older adults with polypharmacy, we found that 68% of older adults were taking one or more medications with a DDI with nirmatrelvir-ritonavir and 21% were prescribed one or more interacting PIMs. Many of these (two thirds) were high risk interactions and some would require advanced deprescribing to allow for treatment with nirmatrelvir-ritonavir (the most obvious example being amiodarone due to its extremely long half-life). In the absence of an advanced plan to deprescribe, many older adults in the cohort would require an alternative COVID-19 therapy because the interactions could not be mitigated by holding the interacting medication. These findings build on our previous research, calling for proactive deprescribing of PIMs among older adults. [12] This would not only reduce the general burden of overmedication commonly observed among 40-50% of older adults, [24] but would also potentially render more people eligible to receive certain COVID-19 therapies. This motivated our secondary study aim which was to craft deprescribing guidance for PIMs that interact with nirmatrelvir-ritonavir to provide clinicians with a practical tool, to help triage deprescribing resources, and to highlight PIMs that should be addressed as soon as possible during the pandemic. The most common high risk interacting PIMs were lipid lowering agents being given for primary prevention in patients with a limited life expectancy. [25] Deprescribing statins in this population has the added benefit of improving quality of life. [25] Also identified were combination antithrombotics/anticoagulants, alfuzosin and tamsulosin in people predisposed to orthostatic hypotension, atypical antipsychotics prescribed for sleep or agitation, and chronic opioids for non-malignancy associated pain. The added benefit of deprescribing these classes of medications is the potential to reduce medication related side effects and harmful ADEs such as All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. bleeding, [26] falls, [27] and fractures. [28] Of note, opioids for chronic non-cancer pain need to be deprescribed well in advance in order to administer nirmatrelvir-ritonavir due to the risk of acute opioid withdrawal in the absence of tapering. Limitations of this study are the theoretical nature of the "drug exposure" to only one treatment for COVID-19; however, with millions of courses of nirmitrelvir-ritonavir purchased worldwide, it is expected to be a common exposure. This analysis could also be replicated for other promising potential outpatient treatments, such as fluvoxamine, which also has several DDIs. [29] We also focused this paper on PIMs; however, the majority of interacting medications were not PIMs. We have provided medication management guidance for many of these medications elsewhere. [12] It is also important to recognize that stopping PIMs requires clinical judgment when formulating a deprescribing plan. The strength of this study is the large sample size of representative community dwelling older adults with polypharmacy who are at high risk of severe COVID-19 complications; arguably, one of the populations most likely to benefit from treatment with nirmatrevir-ritonavir. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. In this cohort, many older adults were prescribed chronic PIMs that had high risk DDIs with nirmatrelvir-ritonavir. Some of these would need to be stopped well in advance of treatment. We suggest clinicians look to proactively deprescribe PIMs to allow older adult populations to safely benefit from the receipt of promising emerging treatments against COVID- All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. We wish to thank the patients who enrolled in the MedSafer study who agreed to participate in research into polypharmacy. Sponsor's role: This study was not funded. MedSafer study [18] contains the primary data from which the present study was derived. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Table 2 for potential triggering conditions); potential inappropriate medications are indicated in bold. PIM= potentially inappropriate medication; CNS= central nervous system; NSAIDs=nonsteroidal antiinflammatories; PDE5i=phosphodiesterase-5-inhibitors. Not listed in this table are the following medications with important drug-drug interactions with nirmatrelvirritonavir: estrogen containing hormone contraceptives; chemotherapies; antifungals (e.g., voriconazole) and antimycobacterials (e.g., rifampin); long-acting inhaled beta agonists (e.g., salmeterol) as these were not collected in the MedSafer study. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 4, 2022. ; https://doi.org/10.1101/2022.03.01.22271254 doi: medRxiv preprint COVID-19 data explorer Centre for Disease Control (CDC). COVID-19 Provisional Counts The COVID-19 Pandemic and Older Adults: Routledge Tracking and controlling the spatiotemporal spread of SARS CoV-2 Omicron variant in South Africa Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants COVID-19) Update: FDA Authorizes First Oral Antiviral for Treatment of COVID-19 The role of antiviral treatment in the COVID-19 pandemic. The Lancet Respiratory Medicine Product Monograph Including Patient Information -Paxlovid. Government of Canada Outpatient therapies for COVID-19: How do we choose? Nirmatrelvir-ritonavir for COVID-19 Effect of Hydroxychloroquine on Clinical Status at 14 Days in Hospitalized Patients With COVID-19 COVID SAFER : Deprescribing Guidance for Hydroxychloroquine Drug Interactions in Older Adults CYP3A4 drug interactions: correlation of 10in vitroprobe substrates The MedSafer Study-Electronic Decision Support for Deprescribing in Hospitalized Older Adults STOPP/START criteria for potentially inappropriate prescribing in older people: version 2 American Geriatrics Society 2019 Updated AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults The MedSafer Study-Electronic Decision Support for Deprescribing in Hospitalized Older Adults: A Cluster Randomized Clinical Trial Study of Oral PF-07321332/Ritonavir Compared With Placebo in Nonhospitalized High Risk Adults With COVID-19 -Full Text View Effect on CYP3A4 activity In Vitro Interaction of the HIV Protease Inhibitor Ritonavir with Herbal Constituents: Changes in P-gp and CYP3A4 Activity Nursing: polypharmacy and medication management in older adults Evidence-Based Deprescribing of Statins in Patients With Advanced Illness Risk of Bleeding With Single, Dual, or Triple Therapy With Warfarin, Aspirin, and Clopidogrel in Patients With Atrial Fibrillation Falls and Fractures With Atypical Antipsychotic Medication Use: A Population-Based Cohort Study Relationship of opioid use and dosage levels to fractures in older chronic pain patients Fluvoxamine for Outpatient COVID-19 to Prevent Hospitalization: A Systematic Review and Meta-Analysis Table 2. Prevalence of Drug-Drug interactions with Hypothetical Nirmatrelvir-ritonavir Exposure AHFS classification Generic drug name Proportion of patients prescribed N(%)